<DOC>
	<DOCNO>NCT00051103</DOCNO>
	<brief_summary>The purpose study determine efficacy oral investigational drug treatment metastatic breast cancer tumor know overexpress HER2/neu .</brief_summary>
	<brief_title>Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line Second-line Herceptin .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>( The patient must meet follow criterion order eligible study . ) Signed inform consent No two prior regimen metastatic breast cancer . Each regimen must contain Herceptin . Refractory Stage IIIb IV breast cancer HER2/neu tumor overexpression Disease progression receive prior chemotherapy regimen Herceptin alone combination chemotherapy . Tumor tissue available testing . 2 week since treatment Herceptin ( alone combination ) . Able swallow retain oral medication Cardiac ejection fraction within institutional range normal measure MUGA ( Multiple Gated Acquisition Scan ) . Adequate kidney liver function Adequate bone marrow function ( The patient meet follow criterion order eligible study . ) Prior regimens include Herceptin . Pregnant lactate . Conditions would affect absorption oral drug Serious medical psychiatric disorder would interfere patient 's safety inform consent . Severe cardiovascular disease cardiac disease require device . Active infection . Brain metastasis . Concurrent cancer therapy investigational therapy . Use oral IV steroid . Unresolved unstable serious toxicity prior therapy . Treatment EGFR ( Endothelial Growth Factor Receptor ) inhibitor Herceptin .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Refractory</keyword>
</DOC>